What is Orforglipron (Foundayo, non-peptide)?

An oral small-molecule GLP-1 receptor agonist (not a peptide); FDA-approved as Foundayo on April 1, 2026 for chronic weight management.

Orforglipron (Foundayo, non-peptide) in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?

36 registered trials · 21 indexed papers · 18 human / 2 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

Orforglipron is described as a once-daily pill that activates the GLP-1 receptor but is a small molecule, not a peptide, so it does not need the food and water restrictions of oral semaglutide.

It is included because it is widely discussed next to GLP-1 peptides.

Mechanism (as described)

  • It binds the GLP-1 receptor in a different way from peptide agonists, with similar downstream effects on appetite and glucose.

Evidence (as described)

  • ACHIEVE-1 (early type 2 diabetes) reported lower HbA1c and weight (Rosenstock et al., N Engl J Med 2025).

Status

FDA-approved April 1, 2026 (Foundayo) for weight reduction and long-term maintenance in adults with obesity, or overweight with a weight-related condition.

Registered human trials (36)

TrialPhaseStatusYearEnrolled
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesPhase 3recruiting2026170
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingPhase 3recruiting2026130
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationPhase 4not yet recruiting202660
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesPhase 4not yet recruiting2026100
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsPhase 3not yet recruiting2026192
IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsPhase 1recruiting2026104
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityPhase 3recruiting20262001
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or OverweightPhase 1completed2025120
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)Phase 3active not recruiting2025974
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1Phase 3active not recruiting2025487
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2Phase 3active not recruiting2025487
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityPhase 3active not recruiting2025800
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesPhase 3active not recruiting2025600
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesPhase 3active not recruiting20251400
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneePhase 3active not recruiting2025800
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightPhase 3recruiting20251000
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseasePhase 3recruiting20251205
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)Phase 3recruiting20257140
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsPhase 1completed202450
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminPhase 3completed2024962
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy ParticipantsPhase 1completed202430
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightPhase 1completed2024533
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)Phase 3completed2024376
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightPhase 3completed2024712
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)Phase 3recruiting2024125
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesPhase 3recruiting2024150
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy ParticipantsPhase 1completed202486
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy ParticipantsPhase 1completed202427
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminPhase 3completed20231698
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskPhase 3completed20232749
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesPhase 3active not recruiting20233127
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesPhase 3completed20231613
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseasePhase 3completed2023238
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AlonePhase 3completed2023559
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesPhase 3completed2023401
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorPhase 3completed2023546

Peer-reviewed studies (21)

PaperAuthorsJournalYearType
Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trialKlein KR et al.Lancet (London, England)2026Randomized Controlled Trial
Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trialYabe D et al.The lancet. Diabetes & endocrinology2026Randomized Controlled Trial
Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical TrialsWharton S et al.Diabetes, obesity & metabolism2026Clinical Trial, Phase III
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trialWelch M et al.Lancet (London, England)2026Randomized Controlled Trial
Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical TrialGiorgino F et al.JAMA2026Randomized Controlled Trial
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trialAronne LJ et al.Nature medicine2026Randomized Controlled Trial
Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or OverweightMa X et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trialRosenstock J et al.Lancet (London, England)2026Randomized Controlled Trial
A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetesOhwaki K et al.Journal of diabetes investigation2026Randomized Controlled Trial
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trialHorn DB et al.Lancet (London, England)2026Randomized Controlled Trial
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy ParticipantsMorse BL et al.Clinical pharmacology in drug development2026Clinical Trial, Phase I
In early T2D inadequately controlled with diet and exercise, once-daily orforglipron reduced HbA(1c) vs. placebo at 40 wkShahid M et al.Annals of internal medicine2025Randomized Controlled Trial
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity TreatmentWharton S et al.The New England journal of medicine2025Randomized Controlled Trial
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetesRosenstock J et al.Diabetes, obesity & metabolism2025Randomized Controlled Trial
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 DiabetesRosenstock J et al.The New England journal of medicine2025Randomized Controlled Trial
Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetesWharton S et al.Cardiovascular diabetology2025Randomized Controlled Trial
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetesPratt EDiabetes, obesity & metabolism2024Randomized Controlled Trial
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 studyFrias JP et al.Lancet (London, England)2023Randomized Controlled Trial
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesityWharton S et al.The New England journal of medicine2023Randomized Controlled Trial
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participantsPratt E et al.Diabetes, obesity & metabolism2023Randomized Controlled Trial
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetesPratt E et al.Diabetes, obesity & metabolism2023Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Orforglipron (Foundayo, non-peptide)?

An oral small-molecule GLP-1 receptor agonist (not a peptide); FDA-approved as Foundayo on April 1, 2026 for chronic weight management.

How many registered human trials study Orforglipron (Foundayo, non-peptide)?

The PeptideWhiz trial index lists 36 registered trials for Orforglipron (Foundayo, non-peptide), the most recent from 2026.

How much published research exists on Orforglipron (Foundayo, non-peptide)?

The PeptideWhiz paper index links 21 PubMed papers to Orforglipron (Foundayo, non-peptide); by study type, 18 human and 2 animal studies.

Which conditions is Orforglipron (Foundayo, non-peptide) researched for?

Atherosclerosis, cardiovascular disease & high blood pressure, Concussion, traumatic brain injury & stroke recovery, Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Osteoarthritis, cartilage loss & avoiding joint replacement.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research